Retinitis Pigmentosa - A Pipeline Analysis Report

Overview of the drug development pipeline for retinitis pigmentosa

Retinitis pigmentosa is a genetic disorder that results in vision loss. It is known to progress over a period and results in complete blindness. Retinitis pigmentosa is caused by mutations in one of over 100 types of genes. The breakdown and loss of cells in the retina are also known to cause retinitis pigmentosa. Patients with this disease generally inherit the disease from their parents. The onset is often in childhood. However, in some cases, the disease does not begin until adulthood. The type and speed of vision loss caused by retinitis pigmentosa differ from person to person and factors, such as the form of the condition. Retinitis pigmentosa can further broadly be classified into three categories namely nonsyndromic, syndromic, and secondary. Nonsyndromic is when the disease occurs alone and does not affect any other sensory organs. While syndromic occurs when retinitis pigmentosa occurs with other neurosensory disorders or developmental abnormalities. Secondary occurs because of the other systemic diseases. The prevalence of the disease is higher in children and young adults compared with the older population. It progresses faster between the age of 20 and 60 years. According to NLM, a part of NIH, retinitis pigmentosa is estimated to affect 100 in every 350,000 to 400,000 people in the US and Europe. The global prevalence is 100 in every 300,000 to 700,000 people. As a result, the rising incidences of the disease are further expected to promote the drug development for retinitis pigmentosa in the forthcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for retinitis pigmentosa. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of retinitis pigmentosa. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Acucela
• AGTC
• Astellas Pharma
• Bayer
• Novartis

Therapeutic assessment of the drug development pipeline for retinitis pigmentosa by route of administration

• Subretinal
• Intravitreal
• Implant
• Intraocular
• Topical

The subretinal route of administration (ROA) involves the application of the drug directly between the photoreceptors and the retinal pigment epithelium in the eye, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for retinitis pigmentosa by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for retinitis pigmentosa are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for retinitis pigmentosa?
• What are the companies that are currently involved in the development of drug molecules for retinitis pigmentosa?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.